Bristol Myers Squibb's acquisition of Mirati Therapeutics is poised to strengthen the former's position in the targeted therapy market, not only with the KRASG12C inhibitor adagrasib but also with Mirati's other assets, including a potential first-in-class PRMT5 inhibitor.

You do not currently have access to this content.